Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

45.54USD
15 Feb 2019
Change (% chg)

$1.04 (+2.34%)
Prev Close
$44.50
Open
$44.74
Day's High
$45.66
Day's Low
$44.36
Volume
154,081
Avg. Vol
256,693
52-wk High
$82.68
52-wk Low
$33.06

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $1,444.21
Shares Outstanding(Mil.): 25.69
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -5.77 -- --
ROI: -61.42 8.92 14.45
ROE: -61.71 10.08 15.96

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

UPDATE 1- Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

Earnings vs. Estimates